Romiplostim to prevent low platelets from chemotherapy in breast cancer
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a drug called romiplostim to prevent low platelet counts (a condition that raises bleeding risk) caused by chemotherapy in people with breast cancer. If you qualify, you may receive this drug to help keep your platelets at a safer level during future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have been diagnosed with breast cancer.
- Your last chemotherapy caused your platelet count to drop very low (below 50), or moderately low (50-75) with a high bleeding risk.
- Your platelet count is currently above 100.
- You have not taken romiplostim before.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if romiplostim, a drug that helps the body make platelets, can speed up platelet recovery after a special type of stem cell transplant from a half-matched donor. It may help reduce bleeding risk during the recovery period.
This trial tests romiplostim, a weekly injection, for patients with ITP (a blood disorder where the body destroys its own platelets) who did not respond to or could not tolerate oral medications. It aims to help raise platelet counts and reduce bleeding risk.
This trial compares two drugs, romiplostim and rhTPO, to help increase platelet counts after a stem cell transplant in people with MDS or aplastic anemia. The goal is to see which drug works better at reducing the need for platelet transfusions.
This trial tests a new version of a drug called romiplostim to help raise platelet counts in breast cancer patients whose platelets drop because of chemotherapy. Raising your platelets may reduce the risk of bleeding and allow you to continue your cancer treatment.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This trial tests a drug called romiplostim to help raise platelet levels in children and young adults (ages 6–24) whose platelets drop due to chemotherapy. It’s for those with solid tumors or other non-marrow cancers who are still getting strong treatment.
Hear when a new Thrombocytopenia Chemotherapy Induced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.